APA (7th ed.) Citation

Parmar, D. V., Kansagra, K. A., Momin, T., Patel, H. B., Jansari, G. A., Bhavsar, J., . . . Jain, M. R. (2023). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose). Clinical pharmacology in drug development, 12(2), 202-211. https://doi.org/10.1002/cpdd.1162

Chicago Style (17th ed.) Citation

Parmar, Deven V., et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)." Clinical Pharmacology in Drug Development 12, no. 2 (2023): 202-211. https://doi.org/10.1002/cpdd.1162.

MLA (9th ed.) Citation

Parmar, Deven V., et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)." Clinical Pharmacology in Drug Development, vol. 12, no. 2, 2023, pp. 202-211, https://doi.org/10.1002/cpdd.1162.